South Korean biotechnology company AbTis announced that the US Patent Trial and Appeal Board has upheld its US patent covering the company’s exclusive AbClick platform. The review was initiated by Anjinmoto, which asserted that the patent failed to meet US requirements for written description, enablement and definiteness.